| abstract |
FIELD: medicine; pharmaceuticals. n SUBSTANCE: invention refers to pharmaceutical industry and medicine, namely to an agent for tumour therapy, active against tumours of mice: lymphatic leukaemia P-388, Ehrlich tumours, Lewis lung epidermoid carcinoma, V-16 melanoma, cervical cancer cervix RShM-5, AKATOL intestinal cancer and adenocarcinoma Ca 755. Proposed agent contains (wt. %): 1.2 % n-{12-(β-d-xylopyranosyl)-5,7-dioxo-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl}pyridine-2-carboxamide; 13.0 % dimethylsulphoxide (DMSO); 47.4 % of Solidone 17PF, 38.4 % of ethyl alcohol (95 %). n EFFECT: invention provides creating a new anticancer agent of precise dosing characterized by high cytostatic effect, good solubility and stability during storage. n 1 cl, 7 tbl |